Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2011. The report details a specific share repurchase transaction executed on March 30, 2011, in accordance with shareholder authority granted at the Annual General Meeting on May 6, 2010.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 550,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,198.5 pence per share; lowest price paid was 1,189.5 pence per share.
- Treasury Shares Held: 493,224,284 shares (representing 8.71% of total issued share capital and 9.54% of total voting rights).
- Shares in Issue: 5,171,206,142 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding share capital through the purchase and subsequent cancellation of 550,000 shares. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure regarding the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Investor Verification Points
- Verify the total number of shares in issue (5,171,206,142) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the current percentage of Treasury shares held (8.71% of issued capital) to assess potential dilution or buyback capacity.
- Note that the purchased shares were cancelled, permanently reducing the share count.